Used in targeted cancer therapy, particularly in the development of antibody-drug conjugates (ADCs). The iodoacetamido group enables site-specific conjugation to thiol groups on monoclonal antibodies, allowing precise delivery of doxorubicin to tumor cells. This selective targeting enhances the cytotoxic effect on cancer cells while minimizing damage to healthy tissues. It is especially valuable in treating hematological malignancies and solid tumors where specific antigen expression allows for effective antibody binding. The compound leverages the potent DNA-intercalating and topoisomerase-inhibiting properties of doxorubicin, combined with the specificity of immunotherapy, improving therapeutic efficacy and reducing systemic side effects.